Development of ST-246® for treatment of poxvirus infections

Viruses

Volumn 2, Issue 11, 2010, Pages 2409-2435

  Jordan, Robert ^a   Leeds, Janet M ^a   Tyavanagimatt, Shanthakumar ^a   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

Author keywords

Antiviral drug; Egress inhibitor; Orthopoxvirus; P37; Smallpox; ST 246; Tecovirimat

Indexed keywords

TECOVIRIMAT;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GENOTOXICITY; HUMAN; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS INFECTION; REVIEW; SMALLPOX; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TREATMENT RESPONSE;

ANIMALIA; MUS; ORTHOPOXVIRUS; POXVIRIDAE; PRIMATES; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 79952132207     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2112409     Document Type: Review

References (80)

1. Fenner, F.; Henderson, D.A.; Arita, I.; Jazek, Z.; Ladnyi, I.D. Smallpox and Its Eradication; World Health Organization: Geneva, Switzerland, 1988; pp. 1-1421.
2. Parker, S.; Nuara, A.; Buller, R.M.; Schultz, D.A. Human monkeypox: An emerging zoonotic disease. Future Microbiol. 2007, 2, 17-34.
3. Mukinda, V.B.; Mwema, G.; Kilundu, M.; Heymann, D.L.; Khan, A.S.; Esposito, J.J. Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group. Lancet 1997, 349, 1449-1450.
4. Monath, T.P.; Caldwell, J.R.; Mundt, W.; Fusco, J.; Johnson, C.S.; Buller, M.; Liu, J.; Gardner, B.; Downing, G.; Blum, P.S.; Kemp, T.; Nichols, R.; Weltzin, R. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-A second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 2004, 8, S31-S44.
5. Baxby, D.; Bennett, M.; Getty, B. Human cowpox 1969-93: A review based on 54 cases. Br. J. Dermatol. 1994, 131, 598-607.
6. Vorou, R.M.; Papavassiliou, V.G.; Pierroutsakos, I.N. Cowpox virus infection: An emerging health threat. Curr. Opin. Infect. Dis. 2008, 21, 153-156.
7. Essbauer, S.; Pfeffer, M.; Meyer, H. Zoonotic poxviruses. Vet. Microbiol. 2010, 140, 229-236.
8. Reynolds, M.G.; Carroll, D.S.; Olson, V.A.; Hughes, C.; Galley, J.; Likos, A.; Montgomery, J.M.; Suu-Ire, R.; Kwasi, M.O.; Root, J.J.; Braden, Z.; Abel, J.; Clemmons, C.; Regnery, R.; Karem, K.; Damon, I.K. A silent enzootic of an orthopoxvirus in Ghana, West Africa: evidence for multi-species involvement in the absence of widespread human disease. Am. J. Trop. Med. Hyg. 2010, 82, 746-754.
9. Vora, S.; Damon, I.; Fulginiti, V.; Weber, S.G.; Kahana, M.; Stein, S.L.; Gerber, S.I.; Garcia-Houchins, S.; Lederman, E.; Hruby, D.; Collins, L.; Scott, D.; Thompson, K.; Barson, J.V.; Regnery, R.; Hughes, C.; Daum, R.S.; Li, Y.; Zhao, H.; Smith, S.; Braden, Z.; Karem, K.; Olson, V.; Davidson, W.; Trindade, G.; Bolken, T.; Jordan, R.; Tien, D.; and Marcinak, J. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 2008, 46, 1555-1561.
10. Fulginiti, V.A.; Papier, A.; Lane, J.M.; Neff, J.M.; Henderson, D.A. Smallpox vaccination: A review, part II. Adverse events. Clin. Infect. Dis. 2003, 37, 251-271.
11. Bray, M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antivir. Res. 2003, 58, 101-114.
12. Lane, J.M.; Ruben, F.L.; Neff, J.M.; Millar, J.D. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J. Infect. Dis. 1970, 122, 303-309.
13. Gubser, C.; Hue, S.; Kellam, P.; and Smith, G.L. Poxvirus genomes: A phylogenetic analysis. J. Gen. Virol. 2004, 85, 105-117.
14. Johnston, J.B.; McFadden, G. Poxvirus immunomodulatory strategies: Current perspectives. J. Virol. 2003, 77, 6093-6100.
15. McLysaght, A.; Baldi, P.F.; Gaut, B.S. Extensive gene gain associated with adaptive evolution of poxviruses. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 15655-15660.
16. Matz-Rensing, K.; Ellerbrok, H.; Ehlers, B.; Pauli, G.; Floto, A.; Alex, M.; Czerny, C.P.; Kaup, F.J. Fatal poxvirus outbreak in a colony of New World monkeys. Vet. Pathol. 2006, 43, 212-218.
17. Yang, G.; Pevear, D.C.; Davies, M.H.; Collett, M.S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, C.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Buller, R.L.; Touchette, E.; Waller, K.; Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; and Jordan, R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 2005, 79, 13139-13149.
18. Bailey, T.R.; Rippin, S.R.; Opsitnick, E.; Burns, C.J.; Pevear, D.C.; Collett, M.S.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Kern, E.R.; Keith, K.A.; Dai, D.; Yang, G.; Hruby, D.; Jordan, R. N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 2007, 50, 1442-1444.
19. Duraffour, S.; Snoeck, R.; de Vos, R.; van Den Oord, J.J.; Crance, J.M.; Garin, D.; Hruby, D.E.; Jordan, R.; De, Clercq E.; Andrei, G. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 2007, 12, 1205-1216.
20. Smith, S.K.; Olson, V.A.; Karem, K.L.; Jordan, R.; Hruby, D.E.; Damon, I.K. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob. Agents Chemother. 2009, 53, 1007-1012.
21. Jordan, R. Siga Technologies, Inc., Corvallis, OR, USA. Unpublished work, 2010.
22. Moss, B. Poxviridae and Their Replication, 4th ed.; Lippincott-Raven, Philadelphia, PA, USA, 2001; pp. 2849-2884.
23. Smith, G.L.; Vanderplasschen, A.; Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 2002, 83, 2915-2931.
24. Byrd, C.M.; Bolken, T.C.; Hruby, D.E. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol. 2002, 76, 8973-8976.
25. Blasco, R.; Moss, B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 1991, 65, 5910-5920.
26. Roper, R.L.; Wolffe, E.J.; Weisberg, A.; Moss, B. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J. Virol. 1998, 72, 4192-4204.
27. Cudmore, S.; Cossart, P.; Griffiths, G.; Way, M. Actin-based motility of vaccinia virus. Nature 1995, 378, 636-638.
28. Payne, L.G. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 1980, 50, 89-100.
29. Payne, L.G.; Kristensson, K. Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J. Gen. Virol. 1985, 66, 643-646.
30. McIntosh, A.A.; Smith, G.L. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J. Virol. 1996, 70, 272-281.
31. Stern, R.J.; Thompson, J.P.; Moyer, R.W. Attenuation of B5R mutants of rabbitpox virus in vivo is related to impaired growth and not an enhanced host inflammatory response. Virology 1997, 233, 118-129.
32. Zhang, W.H.; Wilcock, D.; Smith, G.L. Vaccinia Virus F12L Protein Is Required for Actin Tail Formation, Normal Plaque Size, and Virulence. J. Virol. 2000, 74, 11654-11662.
33. Boulter, E.A.; Zwartouw, H.T.; Titmuss, D.H.; Maber, H.B. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am. J. Epidemiol. 1971, 94, 612-620.
34. Reeves, P.M.; Bommarius, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, A.; Chavan, R.; Feinberg, M.B.; Veach, D.; Bornmann, W.; Sherman, M.; and Kalman, D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 2005, 11, 731-739.
35. Yang, H.; Kim, S.K.; Kim, M.; Reche, P.A.; Morehead, T.J.; Damon, I.K.; Welsh, R.M.; Reinherz, E.L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 2005, 115, 379-387.
36. Vanderplasschen, A.; Mathew, E.; Hollinshead, M.; Sim, R.B.; Smith, G.L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 7544-7549.
37. Vanderplasschen, A., Hollinshead, M.; Smith, G.L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 1997, 78 (Pt. 8), 2041-2048.
38. Husain, M.; Weisberg, A.; Moss, B. Topology of epitope-tagged F13L protein, a major membrane component of extracellular vaccinia virions. Virology 2003, 308, 233-242.
39. Hiller, G. Weber, K. Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. J. Virol. 1985, 55, 651-659.
40. Husain, M.; Moss, B. Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J. Virol. 2002, 76, 7777-7789.
41. Husain, M.; Moss, B. Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles. J. Virol. 2001, 75, 7528-7542.
42. Schweizer, A.; Kornfeld, S.; Rohrer, J. Proper sorting of the cation-dependent mannose 6-phosphate receptor in endosomes depends on a pair of aromatic amino acids in its cytoplasmic tail. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 14471-14476.
43. Orsel, J.G.; Sincock, P.M.; Krise, J.P.; Pfeffer, S.R. Recognition of the 300-kDa mannose 6-phosphate receptor cytoplasmic domain by 47-kDa tail-interacting protein. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9047-9051.
44. Carroll, K.S.; Hanna, J.; Simon, I.; Krise, J.; Barbero, P.; Pfeffer, S.R. Role of Rab9 GTPase in facilitating receptor recruitment by TIP47. Science 2001, 292, 1373-1376.
45. Diaz, E.; Pfeffer, S.R. TIP47: A cargo selection device for mannose 6-phosphate receptor trafficking. Cell 1998, 93, 433-443.
46. Blot, G.; Janvier, K.; Le Panse, S.; Benarous, R.; Berlioz-Torrent, C. Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity. J. Virol. 2003, 77, 6931-6945.
47. Lopez-Verges, S.; Camus, G.; Blot, G.; Beauvoir, R.; Benarous, R.; Berlioz-Torrent, C. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 14947-14952.
48. Murray, J.L.; Mavrakis, M.; McDonald, N.J.; Yilla, M.; Sheng, J.; Bellini, W.J.; Zhao, L.; Le Doux, J.M.; Shaw, M.W.; Luo, C.C.; Lippincott-Schwartz, J.; Sanchez, A.; Rubin, D.H.; Hodge, T.W. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J. Virol. 2005, 79, 11742-11751.
49. Chen, Y.; Honeychurch, K.M.; Yang, G.; Byrd, C.M.; Harver, C.; Hruby, D.E.; Jordan, R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 2009, 6, 44, doi: 10.1186/1743-422X-6-44.
50. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10, 1093-1095.
51. Breman, J.G.; Henderson, D.A. Diagnosis and management of smallpox. N. Engl. J. Med. 2002, 346, 1300-1308.
52. Sofi Ibrahim, M.; Kulesh, D.A.; Saleh, S.S.; Damon, I.K.; Esposito, J.J.; Schmaljohn, A.L.; Jahrling, P.B. Real-Time PCR Assay To Detect Smallpox Virus. J. Clin. Microbiol. 2003, 41, 3835-3839.
53. Hooper, J.W.; Thompson, E.; Wilhelmsen, C.; Zimmerman, M.; Ichou, M.A.; Steffen, S.E.; Schmaljohn, C.S.; Schmaljohn, A.L.; Jahrling, P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 2004, 78, 4433-4443.
54. Kim, M.; Yang, H.; Kim, S.K.; Reche, P.A.; Tirabassi, R.S.; Hussey, R.E.; Chishti, Y.; Rheinwald, J.G.; Morehead, T.J.; Zech, T.; Damon, I.K.; Welsh, R.M.; and Reinherz, E.L. Biochemical and Functional Analysis of Smallpox Growth Factor (SPGF) and Anti-SPGF Monoclonal Antibodies. J. Biol. Chem. 2004, 279, 25838-25848.
55. Bras, G. The morbid anatomy of smallpox. Doc. Med. Geogr. Trop. 1952, 4, 303-351.
56. Smallpox Case Definitions. As described in Guide A of the Smallpox Response Plan and Guidelines, Coordinating Center for Infectious Diseases (CCID) National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID) Division of Bioterrorism Preparedness and Response (DBPR), 2008.
57. Zaucha, G.M.; Jahrling, P.B.; Geisbert, T.W.; Swearengen, J.R.; Hensley, L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 2001, 81, 1581-1600.
58. Stagles, M.J.; Watson, A.A.; Boyd, J.F.; More, I.A.; McSeveney, D. The histopathology and electron microscopy of a human monkeypox lesion. Trans. R. Soc. Trop. Med. Hyg. 1985, 79, 192-202.
59. Fenner, F.; Buller, R.M.L. Mousepox. In Viral Pathogenesis; Nathanson, N., Ed.; Lippincott Raven: Philadelphia, PA, USA, 1997; pp. 535-553.
60. Westwood, J.C.; Boulter, E.A.; Bowen, E.T.; Maber, H.B. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol. 1966, 47, 453-465.
61. Stittelaar, K.J.; Neyts, J.; Naesens, L.; van Amerongen, G.; van Lavieren, R.F.; Holy, A.; De Clercq, E.; Niesters, H.G.; Fries, E.; Maas, C.; Mulder, P.G.; van der Zeijst, B.A.; Osterhaus, A.D. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 2006, 439, 745-748.
62. Stittelaar, K.J.; van Amerongen, G.; Kondova, I.; Kuiken, T.; van Lavieren, R.F.; Pistoor, F.H.; Niesters, H.G.; van Doornum, G.; van der Zeijst, B.A.; Mateo, L.; Chaplin, P.J.; Osterhaus, A.D. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 2005, 79, 7845-7851.
63. Huggins, J.; Goff, A.; Hensley, L.; Mucker, E.; Shamblin, J.; Wlazlowski, C.; Johnson, W.; Chapman, J.; Larsen, T.; Twenhafel, N.; Karem, K.; Damon, I.K.; Byrd, C.M.; Bolken, T.C.; Jordan, R.; Hruby, D. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 2009, 53, 2620-2625.
64. Jordan, R.; Goff, A.; Frimm, A.; Corrado, M.L.; Hensley, L.E.; Byrd, C.M.; Mucker, E.; Shamblin, J.; Bolken, T.C.; Wlazlowski, C.; Johnson, W.; Chapman, J.; Twenhafel, N.; Tyavanagimatt, S.; Amantana, A.; Chinsangaram, J.; Hruby, D.E.; Huggins, J. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 2009, 53, 1817-1822.
65. Huggins, J. United States Army Institute of Infectious Disease (USAMRIID), Frederick, MD, USA. Personal communication, 2010.
66. Esteban, D.J.; Buller, R.M. Ectromelia virus: The causative agent of mousepox. J. Gen. Virol. 2005, 86, 2645-2659.
67. Martinez, M.J.; Bray, M.P.; Huggins, J.W. A mouse model of aerosol-transmitted orthopoxviral disease: Morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch. Pathol. Lab. Med. 2000, 124, 362-377.
68. Smee, D.F. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir. Chem. Chemother. 2008, 19, 115-124.
69. Quenelle, D.C.; Buller, R.M.; Parker, S.; Keith, K.A.; Hruby, D.E.; Jordan, R.; Kern, E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 2007, 51, 689-695.
70. Nalca, A.; Hatkin, J.M.; Garza, N.L.; Nichols, D.K.; Norris, S.W.; Hruby, D.E.; and Jordan, R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir. Res. 2008, 79, 121-127.
71. Sbrana, E.; Jordan, R.; Hruby, D.E.; Mateo, R.I.; Xiao, S.Y.; Siirin, M.; Newman, P.C.; Da Rosa, A.P.; Tesh, R.B. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 2007, 76, 768-773.
72. Berhanu, A.; King, D.S.; Mosier, S.; Jordan, R.; Jones, K.F.; Hruby, D.E.; Grosenbach, D.W. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 2009, 53, 4999-5009.
73. Grosenbach, D.W.; Berhanu, A.; King, D.S.; Mosier, S.; Jones, K.F.; Jordan, R.A.; Bolken, T.C.; Hruby, D.E. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 838-843.
74. Grosenbach, D.W.; Jordan, R.; King, D.S.; Berhanu, A.; Warren, T.K.; Kirkwood-Watts, D.L.; Tyavanagimatt, S.; Tan, Y.; Wilson, R.L.; Jones, K.F.; Hruby, D.E. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008, 26, 933-946.
75. Jahrling, P.B.; Hensley, L.E.; Martinez, M.J.; LeDuc, J.W.; Rubins, K.H.; Relman, D.A.; Huggins, J.W. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15196-15200.
76. Jordan, R. Siga Technologies, Inc., Corvallis, OR, USA. Double blind, randomized, placebo-controlled, repeat-dose efficacy study of the therapeutic window of the proposed primate equivalence of the human dose (400 mg/day) of oral ST-246 polyform I in cynomolgus monkeys infected with monkeypox virus. Unpublished work, 2010.
77. Jordan, R. Siga Technologies, Inc., Corvallis, OR, USA. Double blind, randomized, placebo-controlled, repeat-dose efficacy study of the therapeutic window of the proposed primate equivalence of the humand dose (400 mg/day) of oral ST-246 polyform I in cynomolgus monkeys infected with variola virus. Unpublished work, 2010.
78. Jordan, R.; Tien, D.; Bolken, T.C.; Jones, K.F.; Tyavanagimatt, S.R.; Strasser, J.; Frimm, A.; Corrado, M.L.; Strome, P.G.; Hruby, D.E. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 2008, 52, 1721-1727.
79. Jordan, R.; Chinsangaram, J.; Bolken, T.C.; Tyavanagimatt, S.R.; Tien, D.; Jones, K.F.; Frimm, A.; Corrado, M.L.; Pickens, M.; Landis, P.; Clarke, J.; Marbury, T.C.; Hruby, D.E. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 2010, 54, 2560-2566.
80. Centers for Disease Control and Prevention (CDC). Progressive vaccinia in a military smallpox vaccinee-United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 532-536.